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Abstract: Insulin sensitizing thiazolidinediones (TZDs) are generally considered to work as agonists for the nuclear receptor 
peroxisome proliferative activated receptor-gamma (PPARγ). However, TZDs also have acute, non-genomic metabolic ef-
fects and it is unclear which actions are responsible for the beneﬁ  cial pharmacology of these compounds. We have taken 
advantage of an analog, based on the metabolism of pioglitazone, which has much reduced ability to activate PPARγ. This 
analog (PNU-91325) was compared to rosiglitazone, the most potent PPARγ activator approved for human use, in a variety 
of studies both in vitro and in vivo. The data demonstrate that PNU-91325 is indeed much less effective than rosiglitazone 
at activating PPARγ both in vitro and in vivo. In contrast, both compounds bound similarly to a mitochondrial binding site 
and acutely activated PI-3 kinase-directed phosphorylation of AKT, an action that was not affected by elimination of PPARγ 
activation. The two compounds were then compared in vivo in both normal C57 mice and diabetic KKAy mice to determine 
whether their pharmacology correlated with biomarkers of PPARγ activation or with the expression of other gene transcripts. 
As expected from previous studies, both compounds improved insulin sensitivity in the diabetic mice, and this occurred in 
spite of the fact that there was little increase in expression of the classic PPARγ target biomarker adipocyte binding protein-2 
(aP2) with PNU-91325 under these conditions. An examination of transcriptional proﬁ  ling of key target tissues from mice 
treated for one week with both compounds demonstrated that the relative pharmacology of the two thiazolidinediones cor-
related best with an increased expression of an array of mitochondrial proteins and with expression of PPARγ coactivator 
1-alpha (PGC1α), the master regulator of mitochondrial biogenesis. Thus, important pharmacology of the insulin sensitiz-
ing TZDs may involve acute actions, perhaps on the mitochondria, that are independent of direct activation of the nuclear 
receptor PPARγ. These ﬁ  ndings suggest a potential alternative route to the discovery of novel insulin sensitizing drugs.
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Introduction
Thiazolidinedione insulin sensitizers originated with an empirical discovery by the Takeda Company 
in the late 1970s. Modiﬁ  ed analogs of lipid lowering drugs were found to lower both glucose and 
insulin levels in rodent models of type 2 diabetes (Sohda et al. 1984, 1990, 2002) secondary to 
improved insulin sensitivity (Hofmann and Colca, 1992; Owens, 2002). The ﬁ  rst group of thiazoli-
dinedione compounds that were eventually developed into clinical candidates was chosen solely 
using structure-activity relationships of pharmacology relative to safety in vivo. These compounds 
included troglitazone, which was subsequently removed from the market because of a unique idio-
syncratic hepatotoxicity, and two compounds, rosiglitazone and pioglitazone, which are routinely 
used to treat type 2 diabetes (Day, 1999; Gillies and Dunn, 2000). These compounds are generally 
assumed to work as direct activators of the transcription factor peroxisome proliferative activated 
receptor-gamma (PPARγ) (Olefsky and Saltiel, 2000; Wilson et al. 1996) and new candidates have 
been both selected and evaluated based on their ability to directly activate or partially activate gene 
transcription directed by PPARγ (Leff and Reed, 2002; Sorbera et al. 2001). However recent evidence 
suggests that at least some of the pharmacology of the insulin sensitizers may be independent of 74
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PPARγ (Crosby et al. 2005, Feinstein et al. 2005, 
Konrad et al. 2005). Furthermore, Brunmeier and 
colleagues have shown that a number of these 
compounds (thiazolidinediones and non-thiazoli-
dinedione analogs) have mitochondrial effects 
regardless of whether they are PPAR agonists or 
antagonists (Brunmair et al. 2001, 2004). Simi-
larly it is now clear that compounds that have this 
pharmacology also have anti-inflammatory 
(Chawla et al. 2001; Cuzzocreaa et al. 2004) and 
cell cycle effects (Palakurthi et al. 2001) that are 
clearly not dependent on PPARγ. Moreover, TZDs 
rapidly activate AMP-kinase in vivo in a process 
that is not reliant on activation of PPARγ (LeBras-
seur et al. 2006). It is not clear whether these 
effects may be mediated by a recently identiﬁ  ed 
mitochondrial binding site for the TZDs (Colca 
et al. 2004) or whether the non-PPARγ-mediated 
pharmacology may participate in the insulin 
sensitizing effects of these compounds. One way 
to further deﬁ  ne which mechanisms are important 
for the beneficial pharmacology of these 
compounds is to directly compare close analogs 
that vary in their ability to activate PPARγ—driven 
gene transcription in vitro and in vivo. The current 
studies address the general effects of two such 
similar analogs in an effort to find the key 
elements of the transcriptional regulation that are 
correlated with insulin sensitization.
Materials and Methods
Experimental protocol
Aged-matched male C57 and KKAy mice (8 weeks 
of age) were obtained from Jackson Laboratories, 
acclimated to ad libitum water and mouse chow 
for one week and then dosed with a single oral dose 
of vehicle (1% sodium methyl carboxycellu-
lose/0.01% Tween 20) or thiazolidinedione 
suspension daily. Ancillary experiments showed 
that these conditions and doses produced maximum 
glucose and insulin reductions in the diabetic 
KKAy mice for the respective compounds. 
Following the seventh daily dose, the mice were 
fasted for 4 hours, anesthetized with isoﬂ  urane, 
blood samples were taken from the orbital sinus 
and tissue samples were immediately frozen and 
stored at –80 ºC until the RNA could be extracted 
for RT-PCR and transcriptional proﬁ  ling. Plasma 
was immediately separated and analyzed for 
glucose using an auto-analyzer and insulin by 
radioimmunoassay (Linco, St. Louis). Total RNA 
was isolated using Qiagen RNeasy. RNA was 
ampliﬁ  ed for microarray using Ambion Message-
AmpII. Pre and post-ampliﬁ  cation RNAs were 
veriﬁ  ed for integrity using Agilent Bioanalyzer 
Nano chip. Liver samples were used primarily for 
aP2 expression as a biomarker for PPARγ-
activation. Adipose tissue RNA was taken as a 
measure of global transcriptional changes. The 
animal studies were reviewed and approved by the 
Pﬁ  zer Institutional Animal Care and Use Committee. 
The animal care and use program is fully accredited 
by the Association for Assessment and Accredita-
tion of Laboratory Animal Care, International.
Message and microarray analysis
Real-Time RT-PCR reagents, software and equip-
ment were purchased from Applied Biosystems. 
Taqman reactions were performed in triplicate 
using One-Step RT-PCR Master Mix Reagents with 
the ABI PRISM
®7900 Sequence Detection System. 
Gene expression was calculated using the compar-
ative CT method.
Microarray analysis was performed on Agilent 
Technologies Whole Mouse Genome Microar-
rays. Ampliﬁ  ed RNA was labeled with reagents 
from the Micromax ASAP RNA labeling kit from 
Perkin Elmer. Microarray images were acquired 
using the Agilent Technologies Microarray 
Scanner. Data was extracted using Imagene 5.6 
from Biodiscovery. Data underwent a rigorous 
QC including background normalization and 
segmented regression.
Assays in vitro
The luciferase reporter assay was carried out in 
HUH7 cells bulk-transfected using Fugene-6 to 
express a Gal4-PPARγ-LBD construct and a Beta-
Gal control plasmid as described (Vosper et al. 
2003). Cells were incubated overnight with 6 wells 
per dilution point. Data are a mean of three inde-
pendent experiments. Statistical signiﬁ  cance was 
determined by Student's t-test for PNU-91325 
versus Rosiglitazone by comparing activation of 
luciferase at 1.2, 12, and 33uM. Similar data have 
been obtained in CHO and HepG2 cells and in a 
PPARγ SPA assay (not shown).
Binding of 3H-pioglitazone to solubilized rat liver 
mitochondrial membranes and crosslinking of crude 
liver mitochondrial membranes were conducted as 
previously described (Colca et al. 2004).75
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Activation of AKT was measured as follows:   
HUH7 cells were plated in 96-well plates at a 
density of 15K/well and incubated overnight in 
growth medium to allow attachment. Cells were 
serum-starved overnight then treated with or 
without TZDs for four hours and with or without 
insulin (1nM) for 5 minutes prior to harvest.  In 
some experiments one half of the cells were treated 
with 100nM wortmannin for 1 hour before TZD 
treatment to determine the dependence on activa-
tion of PI-3 kinase. In other experiments, half of 
the cells were also treated with the PPARγ antago-
nist T0070907 (Lee et al. 2002) (TLK) 1-hour 
before TZD treatment to determine whether the 
activation of PPARγ was required.  Following all 
treatments, the cells were harvested and lysates 
were transferred to Meso Scale Discovery’s (MSD) 
Multi-Spot plates where both total and phosphor-
ylated (Ser473) AKT were measured according to 
the manufacturer’s directions.  MSD’s technology 
employs a modiﬁ  ed sandwich ELISA format that 
utilizes electrochemiluminescence technology, 
affording the detection of multiple proteins in a 
multiplexed format.  
Results
PNU-91325 and rosiglitazone 
comparisons in vitro
In the process of evaluating possible oxidative 
metabolites of pioglitazone, a ketone, PNU-91325, 
was synthesized that is not an actual metabolite of 
pioglitazone (Tanis et al. 1996). Preliminary 
studies indicated that this compound had similar 
pharmacology to pioglitazone (Tanis et al. 1996), 
but subsequent evaluations demonstrated very 
weak activation of PPARγ. Published metabolo-
mics studies show this compound may increase 
mitochondrial fatty acid oxidation in vitro more 
than pioglitazone and rosiglitazone (Harrigan et al. 
2006). Figure 1A shows a direct comparison of the 
two approved anti-diabetes drugs versus PNU-
91325 with respect to activation of Gal4-PPARγ-
driven expression of a luciferase reporter in vitro. 
Compared to rosiglitazone, PNU-91325 is a weaker 
PPARγ activator with approximately two orders of 
magnitude reduced afﬁ  nity, but with similar ability 
to compete with the mitochondrial pioglitazone 
binding site (Figure 1B). All of these analogs also 
competed in a similar fashion for the crosslinking 
of mitoNEET as described (Colca et al. 2004) (not 
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Figure 1. PNU-91325, pioglitazone and rosiglitazone activation 
of Gal4-PPARγ versus mitochondrial binding. The structures of 
the thiazolidinediones used in these studies are shown (Top to 
bottom: rosiglitazone, pioglitazone and PNU-91325). A. (upper 
panel) HUH7 cells expressing Gal4-PPARγ were treated with 
doses of thiazolidinediones shown on the abscissa and the 
luciferase response is recorded on the ordinate as discussed in 
the text.  The data are an average and SEM of triplicate experi-
ments with this cell type. *p < 0.05 versus rosiglitazone at the 
same concentration.  Similar data were obtained on other occa-
sions with CHO and HepG2 cells (not shown). B. (lower panel) 
Solubilized liver mitochondrial membranes were incubated with 
3H-pioglitazone in the combined presence of the concentration of 
the compounds shown on the abscissa and as discussed in the 
text.  The data are plotted as the ratio of speciﬁ  c counts without 
competition to those in the presence of the indicated concentration 
of unlabeled competitor.  These data are average of triplicate 
points and SEM  (note: most SEMs fall within the symbols) of a 
single experiment, but are representative of more than three ex-
periments with liver mitochondrial membranes.76
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shown). The structures of the compounds are 
shown in the inset to Figure 1.
Both PNU-91325 and rosiglitazone acutely 
activated the level of AKT phosphorylation in 
HUH7 cells (Fig. 2). This activation occurred in 
the absence and in the presence of a maximally 
effective dose of insulin and appeared to be 
synergistic with insulin (Fig. 2B and 2C). This 
acute action of both TZDs was not dependent on 
activation of PPARγ as it was not affected by pre-
incubation with 10 µM of the PPARγ inhibitor 
T0070907 (Vosper et al. 2003) (Fig. 2B and 2C 
solid symbols versus open symbols). Under these 
conditions, T0070907 completely prevented the 
PPARγ response as measured in Figure 1A (not 
shown). The increased phosphorylation of AKT 
likely occurred secondary to activation of PI-3 
kinase since the effect was largely prevented by 
the inclusion of the PI-3 kinase inhibitor wort-
mannin (100 nM, Figure 2D).
PNU-91325 and rosiglitazone 
comparisons in vivo; lack
of correlation of improved insulin 
sensitivity with activation of PPARγ
Given the interesting differences between PNU-
91325 and rosiglitazone in vitro with respect to 
activation of PPARγ-driven transcription, a 
comparison was undertaken in vivo to determine 
whether changes in gene expression could 
provide some further insight into the pharma-
cology of these compounds. In the first compar-
isons, an evaluation was made into the relative 
ability of these compounds to activate PPARγ—
driven transcription in vivo to establish whether 
the differences that were observed in vitro 
would also occur in vivo. A secondary analysis 
of the tissues from these animals took a more 
global view to look for correlations and differ-
ences in these two TZDs that vary in their ability 
to activate PPARγ.
To determine whether PNU-91325 also produced 
a reduced activation of PPARγ in vivo, mice were 
dosed with maximally effective doses of PNU-
91325 or rosiglitazone, the most effective PPARγ 
activator of these analogs, or vehicle for 7 days. 
As discussed in the Methods section, both 
compounds were dosed to produce their maximal 
effects on insulin sensitivity. The effects of these 
thiazolidinediones on insulin sensitivity are 
shown in Figure 3A. Improvement in insulin 
sensitivity is shown by the large decrease in the 
product of circulating insulin and glucose in the 
thiazolidinedione-treated diabetic KKAy mice. 
Since, as expected, both insulin and glucose were 
decreased by both drugs, the product of the two 
parameters was used to give a single statistic. 
Tissues from these animals were used for genome-
wide transcriptional proﬁ  ling (see below) and 
specific message expression levels were also 
measured by PCR. The expression of hepatic aP2 
was taken as a biomarker for the activation of 
PPARγ—driven transcription. Rosiglitazone-
induced transcription of aP2 in the liver is known 
to be dependent on the expression of PPARγ; this 
may reﬂ  ect differentiation of adipose-like cells 
within the liver (Matsusue et al. 2003, Schadinger 
et al. 2005, Spiegelman 1998) and it thus provides 
a sensitive biomarker for activation of the tran-
scription factor in vivo. As seen in Figure 3B, 
rosiglitazone (20 mg/kg) produced a three-fold 
increase in aP2 message in liver from normal C57 
mice while PNU-91325 produced no change even 
at a ﬁ  ve-fold higher dose. In diabetic KKAy mice 
which have an increased expression of PPARγ in 
the liver, the same dose of rosiglitazone produced 
a more than 20-fold increase in the expression of 
aP2 while PNU-91325, although yielding a 
slightly greater increase in insulin sensitivity 
(Fig. 3A), caused only 25% of the increase in aP2 
message observed with rosiglitazone (Fig. 3D). 
Thus, the relative activation of the PPARγ target 
biomarker aP2 by maximal doses of the two 
compounds in vivo reﬂ  ected the differences in 
PPARγ—driven transcription in vitro and did not 
predict the degree of lowering of plasma glucose 
and insulin.
Increased expression of messages
for mitochondrial proteins correlates 
with improved insulin sensitivity
To gain further information on the global effects of 
the two thiazolidinediones to increase PPARγ—
driven gene transcription, an evaluation of was made 
of the relative expression of 16 genes with estab-
lished PPAR response elements (Desvergne and 
Wahli, 1999; Juge-Aubry et al. 1997) in adipose 
tissue, the tissue with the highest expression of 
PPARγ (Spiegelman, 1998). As seen in Figure 4, 
there was not a consistent increase in the expression 
of these 16 genes in adipose tissue from either 
normal or diabetic mice following treatment with 77
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either compound. Thus, there was not a correlation 
with antidiabetic activity with the increased expres-
sion of transcripts known to be activated by PPARγ 
with either of the TZDs in the metabolically sensi-
tive epidydimal adipose tissue.
To take an unbiased look for transcripts that might 
be coordinately regulated by these two TZDs, global 
transcriptional changes produced by both compounds 
were evaluated by transcriptional proﬁ  ling. A perusal 
of all of these data clearly demonstrated a coordinated 
increase in transcripts of proteins involved in mito-
chondrial structure and function. Detailed evaluation 
of the transcriptional proﬁ  les of adipose tissue taken 
from these mice indicated that there was a general 
increase in mRNA for over 300 genes coding for 
mitochondrial proteins. Moreover, the increased 
insulin sensitivity produced by dosing with PNU-
91325 under these conditions correlated with the 
general increase in these transcripts produced by 
PNU-91325 relative to rosiglitazone (Fig. 5). That is, 
there was a small but consistent increase in the effect 
of PNU-91325 over that of rosiglitazone (1.4-fold), 
and the increase was similar in magnitude to the 
increase seen in overall insulin sensitivity under these 
conditions (2.1-fold, Fig. 3A). These transcriptional 
profiling results were confirmed by quantitative 
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Figure 2. Direct increase in p-AKT in vitro is not dependent on PPARγ activation.
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exposure to the TZDs is shown on the abscissa and the ratio of the increase in pAKT/total AKT is shown on the ordinate.  Data are mean 
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RT-PCR. Examples of the relative differences 
measured by RT-PCR are shown for PGC1α, the 
master regulator of mitochondrial biogenesis (Puig-
server and Spiegelman, 2003), and mitoNEET, a 
putative direct mitochondrial target for the thiazoli-
dinediones (Colca et al. 2004) (Fig. 6A and B). 
Interestingly, PNU-91325 also produced a greater 
induction of PPARα (Fig. 6C) which would be 
expected to drive an increase in the oxidation of free 
fatty acids and contribute to the decrease in circulating 
lipids that is seen with this class of compounds 
(Owens, 2002).
Review of the entire data set (not included here) 
demonstrates that there are numerous compound-
speciﬁ  c effects on relative gene expression, but the 
common changes that correlate with the ability to 
improve insulin sensitivity (i.e. lower circulating 
glucose and insulin concentrations) involve the 
increased expression of mitochondrial proteins and 
increased capability to carry out mitochondrial 
β—oxidation of fatty acids. These actions could 
be driven by a direct effect to increase mitochon-
drial biogenesis secondary to activation of AMP-
kinase (LeBrasseur et al. 2006; Brunmair et al. 
2001). Thus, the key ﬁ  nding of this evaluation is 
that the insulin sensitizing effects of two structur-
ally similar TZDs correlates not with the activation 
of the transcription factor PPARγ, but with a global 
pattern of increased expression of transcripts 
encoding mitochondrial function.
Discussion
These studies compare the effects of two structur-
ally similar thiazolidinedione insulin sensitizing 
agents that vary in their ability to activate the 
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Figure 3. Improvement of insulin sensitivity as compared to activation of the PPARγ biomarker, aP2, produced by PNU-91325 and rosiglitazone. 
C57 normal mice and diabetic KKAy mice were treated orally with a single maximally effective dose of rosiglitazone (20 mg/kg), PNU-91325 
(100 mg/kg) or vehicle for 7 days.  On the 8th day and after a 4 hour fast, circulating glucose and insulin levels were measured.  Fasting 
levels of glucose and insulin averaged 22.7 mM and 3.7 nM, respectively for the diabetic KKAy mice and 12 mM and 0.1 nM, respectively 
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changes in insulin sensitivity.  This statistic is shown for the normal mice in Panel A and for the diabetic KKAy mice in Panel B (mean and 
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# p < 0.05 versus rosiglitazone.79
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Figure 4. Comparison of regulation of PPRE-regulated genes in adipose tissue from normal and diabetic mice.
Data for genes containing PPRE (selected as discussed in the text) were taken from the transcriptional proﬁ  ling of epididymal fat pads of 
KKAy (A) and C57 mice (B) shown in Figure 4.  The respective transcript levels were compared for the gene shown on the abscissa in the 
samples from rosiglitazone-treated mice (gray) and PNU-91325-treated mice (black) versus vehicle (taken as 1).  Data are from all 8 mice 
of each group.  Malic enzyme, supernatant (Mod1), [NM_008615]; Acyl-CoA synthetase long-chain family member 1 (Acsl1),  [NM_007981]; 
Enoyl-Coenzyme A, hydratase/3-hydroxyacyl Coenzyme A dehydrogenase (Ehhadh),  [NM_023737]; Stearoyl-Coenzyme A desaturase 1 
[7530417E14]; 3-hydroxy-3-methylglutaryl-coenzyme A synthase 1. [NM_145942]; Glycerol phosphate dehydrogenase 1, [0610008N20]; 
Apolipoprotein A-I (Apoa1),  [NM_009692]; Apolipoprotein A-II (Apoa2),  [NM_013474]; Apolipoprotein C-III (Apoc3),  [NM_023114]; Fatty 
acid binding protein 4, adipocyte (Fabp4),  [NM_024406]; Lipoprotein lipase (Lpl),  [NM_008509]; CD36 antigen (Cd36),  [NM_007643]; 
Phosphoenolpyruvate carboxykinase 1, cytosolic (Pck1),  [NM_011044]; Fatty acid binding protein 1, liver (Fabp1),  [NM_017399]; Solute 
carrier family 27 (fatty acid transporter), member 1 [NM_011977] (FATP); Acyl-CoA synthetase long-chain family member 1 (Acsl1),  [NM_
007981].80
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nuclear receptor PPARγ both in vitro and in vivo. 
The data do not support the simple model that the 
magnitude of activation of PPARγ regulated gene 
transcription is the sole basis for the pharmacology 
of these compounds. Rather, the data are consistent 
with an alternate hypothesis that non-PPARγ-
dependent actions may contribute to the insulin 
sensitizing pharmacology.
As reviewed in the Introduction, there are a 
variety of acute actions of the TZDs that have been 
shown to be independent of activation of PPARγ. 
To this list we add the ability to activate PI-3 
kinase-dependent phosphorylation of AKT. This 
activation occurred in vitro with or without the 
addition of insulin and was not affected by blockade 
of PPARγ—driven transcription (Fig. 2). AKT lies 
at the center of multiple biochemical control 
mechanisms that affect hormone and cytokine 
action and cell survival and this could play an 
important role in some of the pleiotropic effects of 
these compounds (Cantley, 2002; Fayard et al. 
2005; Ushio-Fukai et al. 1999). It is unknown to 
what extent this and other acute effects of the TZDs 
may mediate the overall pharmacology of these 
compounds, especially those aspects of the 
pharmacology which are manifested over many 
days of treatment. It is important to note, however, 
that many acute effects of the compounds have 
been reported in the literature (Brunmair et al. 
2001; Brunmair et al. 2004; LeBrasseur et al. 2006) 
that include impact on mitochondrial function. We 
also confirmed that these TZDs can alter the 
amount of reactive oxygen and ATP produced by 
isolated mitochondria (not shown). In support of 
the hypothesis that acute effects contribute to 
insulin-sensitizing pharmacology, Lee and Olefsky 
demonstrated that within 15 minutes there is a 
statistically signiﬁ  cant improvement in insulin-
mediated glucose uptake produced by infused 
troglitazone in intact rats (Lee and Olefsky, 1995). 
One possibility may be that while there are acute 
effects of the compounds on molecular processes 
that begin to improve insulin sensitivity, the full 
pharmacology depends on longer term gene 
expression and modiﬁ  cation of cellular and mito-
chondrial function (see below).
It is interesting that the insulin sensitizing 
pharmacology produced by these two analogs was 
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Figure 5. Comparison of the effects of PNU-91325 and rosiglitazone treatment on transcripts for mitochondrial proteins.
Data were extracted from the transcriptional proﬁ  le of >300 mitochondrial proteins from the array data from the mice shown in Figure 3 and 
4 and relative increase with each thiazolidinedione versus vehicle were plotted.  For each of the transcripts, the relative increase produced 
by PNU-91325 versus vehicle is plotted on the ordinate as compared to the relative increase in the same transcript produced by rosiglitazone 
on the abscissa.  On average, the effect of PNU-91325 was 1.4 times that of rosiglitazone.  81
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closely tied to a pattern of gene regulation that 
suggests a pressure to increase mitochondrial 
biogenesis. Recent data have confirmed that 
whereas mitochondrial numbers are decreased in 
diabetes and insulin resistant states, thiazolidine-
dione treatment can result in increased mitochon-
drial biogenesis in man (Bogacka et al. 2005). The 
mechanism for how this may occur remains to be 
deﬁ  ned and may involve processes that are both 
dependent and independent of PPARγ. The recent 
identiﬁ  cation of PGC1α as a potentially direct 
PPARγ target gene suggests a receptor-mediated 
increase in PGC1α expression could be involved 
as an initial step leading to increased mitochondrial 
biogenesis (Hondares et al. 2006). However, as 
discussed above, there is also evidence for direct 
mitochondrial effects of the TZDs (Brunmair et al. 
2001; Brunmair et al. 2004; Crosby et al. 2005; 
Feinstein et al. 2005). Furthermore, new data 
suggest that direct activation of AMP-kinase, 
known to occur with TZD treatment, is capable of 
increasing the expression of both PPARα and 
PGC-1 (Lee et al. 2006), both of which are key 
regulators of fatty acid oxidation. It is possible that 
TZDs may affect redox signaling that results in the 
activation of redox-sensitive enzymatic machinery 
such as AKT, PTEN, AMP-kinase, etc. Interest-
ingly, the mitochondrial protein that may partici-
pate in TZD signaling in mitochondria (Colca et al. 
2004) has been suggested to have a redox sensing 
and/or transducing function (Colca, 2006). Recent 
evidence suggests that this protein, also called 
mitoNEET, is an iron-containing protein that is in 
the outer mitochondrial membrane and plays a key 
role in the regulation of oxidative metabolism 
(Wiley et al. 2007).
The current data suggest that increased transcrip-
tion of mitochondrial proteins is a major feature of 
two compounds that differ widely in their ability to 
activate PPARγ but which share similar pharma-
cology. Thus, key pharmacology of these compounds 
may not require direct activation of the nuclear 
transcription factor PPARγ. Since it is now clear that 
thiazolidinedione-induced edema, the main dose-
limiting side effect of these compounds in patients, 
is likely secondary to activation of PPARγ (Guan 
et al. 2005; Zhang et al. 2005), these results suggest 
a potential way to generate improved therapeutics 
with this mode of action. 
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Figure 6. Effects of PNU-91325 and rosiglitazone on expression of 
PGC1α, mitoNEET and PPARα. RNA was isolated from the epi-
didymal fat pads of diabetic KKAy mice treated with vehicle (lined), 
rosiglitazone (gray) or PNU-91325 (black) bars.  The expression of 
transcripts relative to vehicle was determined for PGC1α (A), 
mitoNEET (B) and PPARα (C) (data are mean and SEM; n = 8). 
*p < 0.05 versus vehicle. # p < 0.05 versus rosiglitazone.82
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